Avisi Technologies, LLC Wins “Best of the Best” at Mid Atlantic Bio Angels’ Year-End 1st Pitch Life Science Competition

Scotch Plains, New Jersey, UNITED STATES

NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Mid-Atlantic Bio Angels (MABA) announces today that Avisi Technologies, LLC, which develops an eye implant for glaucoma treatment, was named “Best of the Best” by the audience at MABA’s final 1st Pitch Life Science event for 2018.  The event was held on December 10th at the Alexandria Center in New York City.

“Each year we are impressed with the companies that win best in show over the course of the year and we have continued to be impressed by the progress made by Avisi even since their October win,” commented Yaniv Sneor, MABA co-founder and president of Blue Cactus Consulting.  “They continued to evolve their presentation and demonstrated the spirit of these events by rounding out an already compelling story, which has the potential to provide a solution for millions of people suffering from glaucoma.”

Philadelphia-based Avisi Technologies, LLC (https://www.avisitech.com) is currently developing a nanoscale eye implant for glaucoma that reduces intraocular pressure, surgery time, patient discomfort and risk of blindness. The company’s product, VisiPlate, is thousands of times thinner than competitors, mitigates risk of excessive scar tissue and post-operative problems such as double vision, and is easier to monitor by ophthalmologists after surgery.

“We’re grateful for the opportunity to share our vision for a healthier world at the 1st Pitch Life Sciences events and have found the feedback we’ve received there to be valuable and actionable.  We’re very honored to receive the ‘Best of the Best’ award so soon after our initial presentation back in October,” said Rui Jing Jiang, CEO of Avisi.

About Avisi Technologies
Avisi (www.avisitech.com) is a pre-clinical stage medical devices company headquartered in Philadelphia, PA. Avisi is developing VisiPlate, a nanotechnology-enabled ocular implant for treating glaucoma. Glaucoma is the world’s leading cause of irreversible blindness and will affect 80 million people globally by 2020. Avisi is currently funded via non-dilutive grants and awards from the University of Pennsylvania, VentureWell E-Teams, Ben Franklin Technology Partners Fabnet and IPart, and others. Avisi is a member of Johnson & Johnson’s JLABS/JPOD incubator.

About 1st Pitch Life Science
At a 1st Pitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 10-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company’s presentation, business model and perceived viability in the market.

About MABA
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, physicians and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA’s goal is to create an environment where the depth of investors’ knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.

Jules Abraham
JQA Partners, Inc.